With 85 molecules under development and 3 approvals to date, it seems that bispecific antibodies may be the novel therapeutic booming class on the market.
Beyond the mechanistic advantages, bsAbs offer the possibility to combine in one single molecule the potential of two different antibodies without the related cost of two parallel development programs.
But with the victory, comes the flip side of the coin. In fact, a pretty ancient coin.
They are sometimes qualified as an antagonist, sometimes as an agonist. Sometimes named inductive, sometimes repressive, sometimes blocking, or sometimes neutralizing. But always called antibodies.
Have you ever guessed what it was about?
Yes, that’s them, the biologically active antibodies.
Not a week goes by without a scientific article dealing with the microbiota. And we often hear that understanding the microbiota is explaining our illnesses. But what is exactly the microbiota and how does it influence our condition?
An introduction to our inner forest or what is more commonly called our second brain...